Norden Group LLC Grows Stock Holdings in Boston Scientific Corporation $BSX

Norden Group LLC lifted its position in Boston Scientific Corporation (NYSE:BSX) by 442.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 15,257 shares of the medical equipment provider’s stock after buying an additional 12,443 shares during the period. Norden Group LLC’s holdings in Boston Scientific were worth $1,490,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at $26,000. Sound Income Strategies LLC increased its position in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares in the last quarter. Steph & Co. purchased a new stake in Boston Scientific in the third quarter valued at about $25,000. 1248 Management LLC acquired a new stake in Boston Scientific in the first quarter worth about $26,000. Finally, Kilter Group LLC purchased a new stake in shares of Boston Scientific during the second quarter worth about $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

NYSE:BSX opened at $96.00 on Friday. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The firm has a market cap of $142.31 billion, a price-to-earnings ratio of 51.34, a PEG ratio of 1.94 and a beta of 0.67. The firm’s fifty day moving average is $98.60 and its two-hundred day moving average is $101.10.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same quarter last year, the business posted $0.63 EPS. The company’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 143,095 shares of company stock valued at $14,228,950. 0.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

BSX has been the subject of several research analyst reports. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $118.00 to $125.00 in a research report on Monday, September 8th. BTIG Research reaffirmed a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a report on Friday, November 21st. Barclays boosted their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Canaccord Genuity Group reduced their target price on Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. Finally, Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Boston Scientific has a consensus rating of “Buy” and an average target price of $124.85.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.